GlaxoSmithKline will apparently not have to worry about competition from generic Advair soon according to an article at FT.com.
According to the article, Teva Pharmaceuticals, the company hoping to create a generic Advair product, told its investors that obtaining appropriate regulatory clearance for a generic Advair has been difficult. Rather than pursue generics, Teva intends to push on with their own respiratory products. "One of the key pillars of Teva's long term strategy is the expansion of our branded business and our respiratory franchise will play an important role in this growth," said Shlomo Yanai, Teva's President and Chief Executive Officer. "Over the next five years, and beyond, Teva's unique product portfolio and robust pipeline will enable us to significantly expand our presence in the global respiratory market. We are very enthusiastic about the many opportunities ahead for our respiratory business."
